Buy 3 and get the 4th FREE!* | Learn More >>
13216
IGFBP3 Antibody
Primary Antibodies

IGFBP3 Antibody #13216

Reviews ()
Citations (1)

We recommend the following alternatives

# Product Name Application Reactivity
  • WB
  • IP
H

Supporting Data

REACTIVITY
SENSITIVITY
MW (kDa) 40
SOURCE Rabbit

Application Key:

  • W-Western
  • IP-Immunoprecipitation
  • IHC-Immunohistochemistry
  • ChIP-Chromatin Immunoprecipitation
  • IF-Immunofluorescence
  • F-Flow Cytometry
  • E-P-ELISA-Peptide

Species Cross-Reactivity Key:

  • H-Human
  • M-Mouse
  • R-Rat
  • Hm-Hamster
  • Mk-Monkey
  • Mi-Mink
  • C-Chicken
  • Dm-D. melanogaster
  • X-Xenopus
  • Z-Zebrafish
  • B-Bovine
  • Dg-Dog
  • Pg-Pig
  • Sc-S. cerevisiae
  • Ce-C. elegans
  • Hr-Horse
  • All-All Species Expected

Storage:

Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody.

Specificity / Sensitivity

IGFBP3 Antibody recognizes endogenous levels of total IGFBP3 protein.

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ser155 of human IGFBP3 protein. Antibodies are purified by protein A and peptide affinity chromatography.

Background

Insulin-like growth factor (IGF) signaling plays a major role in regulating the proliferation and metabolism of normal and malignant cells. Insulin-like growth factor-binding proteins (IGFBPs) play an integral role in modifying IGF actions in a wide variety of cell types. The six IGFBP family members share a high affinity for IGF binding and are structurally related, but are encoded by distinct genes (1). IGF binding proteins can exert stimulatory or inhibitory effects by controlling IGF availability through high affinity binding of IGF at the carboxy-terminal domain (2,3). IGFBP3 is the most abundant serum IGF binding protein and the main mediator for IGF-I bioactivities. IGFBP3 also binds IGF-II, insulin, and other cellular and extracellular components to regulate cell growth, development, and apoptosis through both IGF-dependent and IGF-independent mechanisms (4-8). Research studies describe correlations between increased IGF-I levels and reduced levels of IGFBP3 with increased risks of developing cancer, including breast, colon, lung, and prostate cancer (2).

  1. Hwa, V. et al. (1999) Endocr Rev 20, 761-87.
  2. Yu, H. and Rohan, T. (2000) J Natl Cancer Inst 92, 1472-89.
  3. Martin, J.L. and Baxter, R.C. (2011) Growth Factors 29, 235-44.
  4. Zapf, J. et al. (1990) J Biol Chem 265, 14892-8.
  5. Coverley, J.A. and Baxter, R.C. (1997) Mol Cell Endocrinol 128, 1-5.
  6. Ingermann, A.R. et al. (2010) J Biol Chem 285, 30233-46.
  7. Liu, B. et al. (2000) J Biol Chem 275, 33607-13.
  8. Baxter, R.C. (2001) Mol Pathol 54, 145-8.

Pathways & Proteins

Explore pathways + proteins related to this product.

For Research Use Only. Not For Use In Diagnostic Procedures.

Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
Tween is a registered trademark of ICI Americas, Inc.

To Purchase # 13216